The latest financial results of the armed enterprises announced: Murray Medical, Daan gene, Wantai bio...

Pharmaceutical Network January 14th, under the new crown outbreak, various industries are in turmoil, forced to face a shutdown of enterprises are not in the minority.
But in our biopharmaceutical industry, whether it is the medical device sector or biological products, still achieved a proud performance, this is probably the greatest reward for all struggling medical people in the front line! Net profit is up to more than 10 times higher, the annual results of well-known machinery enterprises announced on January 11, according to incomplete statistics show that as of January 10, 2021, 656 listed companies have disclosed the 2020 annual results forecast.
is worth noting that among the companies that have disclosed their 2020 annual results, there are no shortage of well-known arms companies.
, the market value of Meirui Medical, Wanhua Chemical and Wantai Bio has exceeded 100 billion yuan.
500 billion! Murray Medical is named after Murray Medical, a domestic manufacturer of high-tech medical equipment research and development, with its main business covering three major areas: life information and support, in-body diagnosis, and medical imaging.
affected by the new crown outbreak, Murray Medical and 2020 also recently laid out orthopaedic supplies and veterinary equipment in two areas.
December 30, 2020, Murray Medical with the day's closing price of 413 yuan, successfully broke through the 500 billion market value mark, the domestic medical device industry leader is really famous! Earlier, in its earnings forecast, Myer Medical said it expected full-year 2020 operating income of RMB19.87 billion to RMB21.52 billion, up 20%-30% from a year earlier, and that net profit attributable to shareholders of the parent company is expected to be RMB6.08 billion to RMB6.55 billion, up 30%-40% from a year earlier.
seems to have done very well.
: Listed companies announced and, in the semi-annual report before Myer Medical, said the main growth in earnings was in the life information and support business outbreak.
first half of this year, Myer Medical's life information and support business achieved revenue of 5.343 billion yuan, up 62.26% YoY.
is mainly due to the outbreak of new crown pneumonia in the first half of the global outbreak, the company's life information and support business monitors, ventilators, infusion pumps and medical imaging business portable color super, mobile DR demand has increased significantly, the company's life information and support business pull is particularly obvious.
addition, in the in-body diagnostics business, Murray achieved revenue of 3.030 billion yuan in the first half of the year, up 6.49% YoY, and medical imaging business achieved revenue of 2.105 billion yuan, up 6.67% YoY.
although the outbreak has affected the hospital's routine emergency, surgical and medical examinations, the domestic market demand has gradually returned to normal levels.
same time, the outbreak has driven an increase in demand for new coronary antibody reagents, portable ultrasound, and mobile DR, resulting in growth in in-body diagnostics and medical imaging business as a whole.
notable, Murray Medical introduced new crown anti-medical reagent products to overseas markets starting in the second quarter, making up for some of the impact of the outbreak on the routine in-body diagnostic reagent business.
and according to TheRae Medical public financial results revealed that the current national collection of its company's business has not had a great impact! Net profit rose more than 10 times: In addition to Myer Medical, 36 companies expect net profit attributable to shareholders of listed companies to grow more than twice for the full year, and six more expect net profit to grow more than 10 times, according to the 2020 annual results of 656 listed companies.
, the company's full-year profits both rose sharply, helped by a significant increase in demand for testing reagents driven by the new crown outbreak.
part of the company expected to grow significantly in 2020 at a glance Da'an gene - is a relying on Zhongshan University research platform, molecular diagnostic technology-led, set clinical testing reagents and instruments research and development, production, sales and the national chain of independent medical laboratory clinical testing services as one of the biopharmaceutical high-tech enterprises.
2020 earnings are expected to exceed 2 billion yuan, up 20.70 times to 22.87 times year-on-year, according to the company's earnings forecast.
Prior to the end of August 2020, DaanGen released a semi-annual results report that in 2020, Daan Gene's first-half net income attributable to shareholders of listed companies was about 778 million yuan, up 1186.48 percent year-on-year, and operating income was about 2.133 billion yuan, up 313.63 percent year-on-year, with underlying earnings per share of 0.8875 yuan, up 1186.23 percent year-on-year.
reporting period, in the face of the new coronavirus nucleic acid testing kit and nucleic acid testing equipment, related supplies demand increased significantly, The new coronavirus nucleic acid testing kit of the Daan gene quickly and efficiently entered the market, and actively participated in the domestic provinces of the new crown reagent centralized procurement tender, one of the only in the domestic provinces centralized procurement of all the winning enterprises.
At the same time, in the operation of the product line, Da'an gene in public health, infectious diseases and other areas related to the rapid development of the situation, eugenics, precision medicine, blood screening, scientific research services and other product lines have maintained stable development.
December 21, 2020, Da'an Gene officially announced that the company's shareholders were changed from Zhongshan University to Guangzhou Financial Holdings Group Co., Ltd., with a 100% shareholding ratio and the legal representative changed to Xue Zheqiang.
, according to the announcement, after the change of equity, the controlling shareholder of the company remains unchanged and remains the controlling shareholder of China University.
Oriental Biological Disclosure Data show that Oriental Bio is a company specializing in in vitro diagnostic product research and development, production and sales, has now completed from antigen antibodies and other biological raw materials, to in vitro diagnostic reagents and in vitro diagnostic instruments of the entire industrial chain layout, forming a POCT instant diagnostic reagents as the leading products, focusing on the development of molecular diagnostics, biological raw materials, diagnostic instruments and liquid biochips and other products business pattern.
company's products are mainly used in drug testing, infectious disease testing, eugenics and eugenics testing, tumor marker detection and heart muscle marker testing.
drug testing and infectious disease detection are the two core product line of the issuer, accounting for more than 75% of the main business revenue.
company mainly provides in-body diagnostic reagents to overseas medical device distributors, and export revenue is more than 94% of the company's revenue.
2020 net profit is expected to be RMB1,556 million, up about 1795.1% YoY, or about 18 times, according to the company's January 6, 2021 results.
financial results show that the main performance growth is mainly due to the reporting period the company quickly developed a series of new crown detection products, the first half of the focus to promote the new coronavirus (2019-nCoV) IgM/IgG anti-medical test kit (collosus gold method) marketization, the second half of the focus to promote the new coronavirus antigen rapid test paper (collective gold method) marketization, prompting the company's overall sales breakthrough in 2020.
After the outbreak era development opportunities are obvious, the future of the medical device industry is obvious, with the outbreak of the new crown epidemic in early 2020, the global demand for medical equipment and materials once increased, medical imaging, medical equipment, masks, temperature guns, protective clothing and other medical protective supplies ushered in the development opportunity.
2020, many medical enterprises seize the "wind mouth", a large number of head medical enterprises in the equipment industry at home and abroad market expansion at the same time, the company's performance has ushered in rapid growth.
can be said that the new crown outbreak-related medical supplies gap to the medical device industry has brought a certain degree of good.
from the future development plans of major enterprises, the post-epidemic era, the medical sector will remain the focus of market attention.
predictable, after the normal outbreak, the medical device field is bound to usher in more development opportunities.